Indications |
Oral Benign gastric and duodenal ulceration Adult: Initially, 800 mg as a single daily dose given at bedtime for at least 4 wk for duodenal ulcers and 6 wk for gastric ulcers. Maintenance: 400 mg once daily at bedtime or bid.
Oral Stress ulceration of upper gastrointestinal tract Adult: 200-400 mg every 4-6 hr.
Oral Prophylaxis of acid aspiration during general anaesthesia Adult: 400 mg is given orally 90-120 minutes before induction of anaesthesia or at the start of labour and up to 400 mg may be given every 4 hr if necessary.
Oral Gastro-oesophageal reflux disease Adult: 400 mg 4 times daily or 800 mg bid for 4-8 wk.
Oral Zollinger-Ellison syndrome Adult: 300-400 mg 4 times daily, increase dose if necessary.
Oral Non-ulcer dyspepsia Adult: Up to 200 mg 4 times daily.
Oral Prophylaxis of nocturnal heartburn Adult: 100 mg at night.
Oral Pancreatic insufficiency Adult: 800-1600 mg daily in 4 divided doses, to be taken 60-90 minutes before meals.
Intravenous Stress ulceration of upper gastrointestinal tract Adult: 200 mg every 4-6 hr. Special Populations: Renal impairment: Dose reduction based on creatinine clearance. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Contraindications |
Hypersensitivity, lactation. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warnings / Precautions |
Impaired renal and hepatic function. Age >50 yr; CV impairment. Pregnancy. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse Reactions |
Diarrhoea, dizziness, tiredness, rash, headache, CNS disturbances, arthralgia, myalgia, gynaecomastia, alopoecia, blood dyscrasias, nephritis, hepatitis, pancreatitis, granulocytopenia, hypersensitivity reactions. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Overdose Reactions |
Overdosage may lead to respiratory failure and tachycardia that may be controlled by assisted respiration and admin of a β-blocker. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drug Interactions |
Absorption reduced by antacids. May potentiate anticoagulants, phenytoin, theophylline, benzodiazepines, β-blockers, lidocaine. Procainamide clearance is reduced. Reduced absorption of ketoconazole and itraconazole. May enhance gastric mucosal irritation when taken with ethanol. Avoid concurrent use with clopidogrel. See Below for More cimetidine Drug Interactions |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Food Interactions |
Absorption delayed. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mechanism of Actions |
Cimetidine competitively inhibits histamine at H2-receptors of the gastric parietal cells resulting in decreased gastric acid secretion, gastric volume and hydrogen ion concentration. It is a potent inhibitor of metabolism in the hepatic mixed-function oxidase systems. It is also used in patients with pancreatic insufficiency to reduce the breakdown of pancreatic enzyme supplements. Onset: 1 hr. Duration: 4-6 hr. Absorption: Readily absorbed from the GI tract; peak plasma concentrations after 1-3 hr. Food delays the rate and slightly decreases extent of absorption. Distribution: Widely distributed in the body; crosses the placental barrier and appears in breast milk. Protein-binding: 20%. Metabolism: Partially hepatic; converted to the sulfoxide and to hydroxymethylcimetidine. Excretion: Urine (as unchanged); 2 hr (elimination half-life). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Administration |
Should be taken with food. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ATC Classification |
A02BA01 - cimetidine ; Belongs to the class of H2-receptor antagonists. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Available As |
|
Cimetidine
Post Review about Cimetidine Click here to cancel reply.
Cimetidine Containing Brands
Cimetidine is used in following diseases
Drug - Drug Interactions of Cimetidine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.